Ralimetinib is an ATP-competitive p38alpha and p38beta MAPK inhibitor with an IC50 of 5.3 nmol/L against human p38alpha and an IC50 of 3.2 nmol/L against human p38beta. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma[1][2].
Molecular Weight:
420.53
Purity:
98.58
CAS Number:
[862505-00-8]
Formula:
C24H29FN6
Target:
Autophagy,p38 MAPK
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
